<DOC>
	<DOCNO>NCT02561988</DOCNO>
	<brief_summary>This Phase 1 , open-label , dose-escalation study design evaluate safety , tolerability , pharmacokinetics ( PK ) , pharmacodynamics ( PD ) antineoplastic activity BLU-285 , administer orally ( PO ) , adult patient advanced systemic mastocytosis relapse refractory myeloid malignancy . The study consist 2 part , dose-escalation part ( Part 1 ) expansion part ( Part 2 ) .</brief_summary>
	<brief_title>Study BLU-285 Patients With Advanced Systemic Mastocytosis ( advSM ) Relapsed Refractory Myeloid Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Mastocytosis</mesh_term>
	<mesh_term>Mastocytosis , Systemic</mesh_term>
	<mesh_term>Leukemia , Mast-Cell</mesh_term>
	<criteria>For Part 1 : Patients must one follow diagnosis : Aggressive systemic mastocytosis ( ASM ) confirm World Heath Organization ( WHO ) diagnostic criterion . Systemic mastocytosisassociated hematologic nonmast cell disease ( SMAHNMD ) confirm WHO diagnostic criterion , patient also least 1 Cfinding attributable systemic mastocytosis ( SM ) . The AHNMD must myeloid , follow exception exclude : Acute myeloid leukemia ( AML ) , Myelodysplastic syndrome ( MDS ) high highrisk define International prognostic scoring system myelodysplastic syndrome ( IPSSR ) Philadelphia chromosome positive malignancy . Mast cell leukemia ( MCL ) confirm per WHO diagnostic criterion . Histologically cytologically confirm myeloid malignancy confirm IWGMRT WHO diagnostic criterion relapse refractory standard treatment . AML , MDS high highrisk define IPSSR , Philadelphia chromosome positive malignancy exclude . Upon discussion sponsor , relapse refractory , potentially BLU285responsive hematologic neoplasm ( e.g. , evidence aberrant KIT platelet derive growth factor receptor ( PDGFR ) signal ) may consider enrollment . For Part 2 : Group 1 : ASM confirm WHO diagnostic criterion . Group 2 : SMAHNMD confirm WHO diagnostic criterion , also least 1 Cfinding attributable SM . The AHNMD must myeloid , follow exception exclude : AML , MDS high highrisk define IPSSR , Philadelphia chromosome positive malignancy . Group 3 : MCL confirm per WHO diagnostic criterion . Eastern Cooperative Oncology Group ( ECOG ) performance status 03 . QT interval correct use Fridericia 's formula ( QTcF ) &gt; 470 millisecond Platelet count &lt; 25,000/mL Absolute neutrophil count &lt; 500/mL Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 3 x upper limit normal ( ULN ) ; &gt; 5 × ULN associate clinically suspect liver infiltration mastocytosis another disease patient enrol study Total bilirubin &gt; 1.5 × ULN ; &gt; 3 × ULN associate liver infiltration disease treat presence Gilbert 's Disease Estimated ( CockroftGault formula ) measure creatinine clearance &lt; 40 mL/min Brain malignancy metastasis brain History seizure disorder requirement antiseizure medication Known risk intracranial bleeding , brain aneurysm history subdural subarachnoid bleeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>